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ABSTRACT 
Cancer mucosa antigens comprise an emerging category of self-antigens expressed 
normally in immunologically privileged mucosal compartments and universally by their 
derivative tumors (1, 2).  These antigens leverage the established immunological 
partitioning of systemic and mucosal compartments (3, 4), limiting tolerance opposing 
systemic antitumor efficacy (5).  An unresolved issue surrounding self-antigens as 
immunotherapeutic targets is autoimmunity following systemic immunization (6-8).  In 
the context of cancer mucosa antigens, immune effectors to self-antigens risk 
amplifying mucosal inflammatory disease promoting carcinogenesis (9).  Here, we 
examined the relationship between the efficacy of immunity to the intestinal cancer 
mucosa antigen GCC to protect against systemic colon cancer metastases and its 
impact on inflammatory bowel disease and carcinogenesis in mice.  Immunization with 
GCC-expressing viral vectors opposed nascent tumor growth in mouse models of 
pulmonary metastasis reflecting systemic lineage-specific tolerance characterized by 
CD8+, but not CD4+, T cell or antibody responses.  Responses protecting against 
systemic metastases spared intestinal epithelium from autoimmunity, and systemic 
GCC immunity did not amplify chemically-induced inflammatory bowel disease.  
Moreover, GCC immunization failed to promote intestinal carcinogenesis induced by 
germline mutations or chronic inflammation.  The established role of CD8+ T cells in 
antitumor efficacy, but CD4+ T cells in autoimmunity, suggest lineage-specific 
responses to GCC are particularly advantageous to protect against systemic 
metastases without mucosal inflammation.  These observations support the utility of 
GCC-targeted immunotherapy in patients at risk for systemic metastases, including 
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those with inflammatory bowel disease, hereditary colorectal cancer syndromes, and 
sporadic colorectal cancer. 
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INTRODUCTION 
A principle obstacle to cancer immunotherapy is the limited availability of antigens that 
are tumor-specific, immunogenic and universally expressed by patients (10).  In the 
absence of such targets, anticancer immune responses are directed to tissue, rather 
than tumor, -specific antigens.  Limitations to employing self-antigens include tolerance, 
which restricts antitumor immunity, and therapy-induced autoimmunity (11).  These 
restrictions have been circumvented by employing self-proteins, including cancer testis 
antigens, expressed in immune-privileged compartments (12).  Their expression in 
tumors outside those compartments offers opportunities for immunological responses 
essentially to tumor-specific antigens.  However, this approach has been limited by the 
heterogeneous expression of these antigens by tumors. 
This theme of immune segregation has been extended recently to the expression of 
mucosa-restricted antigens by tumors, exploiting the asymmetry in immunological 
cross-talk between mucosal and systemic compartments (2).  This asymmetry offers 
unique benefits reflecting the nexus of immunological privilege, limiting systemic 
tolerance to mucosal antigens, which promotes antitumor responses, and 
immunological partitioning, which protects mucosae from systemic immune responses, 
limiting autoimmunity (3, 4).  These observations suggest a previously unappreciated 
paradigm for tumors originating in mucosae, in which vaccination with cancer mucosa 
antigens produces effective therapeutic responses opposing systemic metastases 
without inducing mucosal inflammation and autoimmunity (1, 2, 5). 
Guanylyl cyclase C (GCC) is a member of the guanylyl cyclase family of receptors, 
which convert GTP to the second messenger cyclic GMP (13).  GCC is exclusively 
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expressed by intestinal epithelial cells, and uniformly over-expressed by primary and 
metastatic colorectal tumors (14-16).  GCC is the index example of cancer mucosa 
antigens, reflecting expression normally restricted to mucosae, but universally bridging 
the central immune compartment by tumor metastasis in all patients.  Indeed, 
immunization with viral vectors containing GCC provides protection in prophylactic and 
therapeutic mouse models of parenchymal colon cancer metastases (1, 2, 5).   
The mucosal immune system discriminates between normal antigens and autoantigens 
to which a response is inappropriate and invading microorganisms to which a response 
is protective.  Occasionally, protective tolerance is lost producing inflammatory bowel 
disease, reflecting barrier disruption and exposure of mucosal antigens to dendritic cells 
in the context of costimulatory signals provided by bacterial pathogens, resulting in 
pathologic T cell responses (17-20).  Of significance, patients with inflammatory bowel 
disease have a 10% - 50% risk of developing colorectal cancer (21) reflecting tumor 
promotion by chronic inflammation (22).  Indeed, intestinal inflammation predisposes 
mice to tumor induction by carcinogens or germline mutations (23, 24). 
These foregoing observations bring into specific relief issues of safety of 
immunotherapy targeting cancer mucosa antigens, and the risk of autoimmune disease 
and inflammation-associated cancer.  These issues are underscored by the potential 
application of such vaccines to prophylaxis of metastases in patients at greatest risk for 
metastatic tumors, particularly patients with inflammatory bowel disease  and hereditary 
colon cancer syndromes (25).  In those clinical populations, the convergence of ongoing 
barrier disruption with induction of mucosally-targeted immune effector cells could 
exacerbate intestinal inflammation leading to carcinogenesis.  These considerations 
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highlight the potential risk for GCC-targeted immunity to amplify mucosal inflammation 
and intestinal tumorigenesis.  Here, we explored the relationship between the 
therapeutic efficacy of GCC immunization to protect against metastatic colorectal 
cancer and its impact on autoimmunity and tumorigenesis in mouse models of 
inflammatory bowel disease and intestinal carcinogenesis. 
MATERIALS AND METHODS 
Mice.  C57BL/6 and BALB/c mice were obtained from the NCI Animal Production 
Program (Frederick, MD).  GCC-deficient (GCC-/-) and wild-type (GCC+/+) C57BL/6 
littermates mice were described previously (5, 26).  APCmin/+ mice were acquired from 
Jackson Laboratories (Bar Harbor, Maine).  Animal protocols were approved by the 
Thomas Jefferson University Institutional Animal Care and Use Committee. 
Recombinant viruses.  GCC and control adenovirus (AV), rabies virus (RV) and 
vaccinia virus (VV) were described previously (5).  NP/SIINFEKL-AV was also 
described previously (27).  For immunizations, mice received 1x108 IFU of adenovirus, 
1x107 FFU of rabies, or 1x107 PFU vaccinia virus by IM injection of the anterior tibialis. 
Cell lines.  C57BL/6-derived MC38 colon cancer cells were provided by Jeffrey Schlom 
(National Cancer Institute, National Institutes of Health, Bethesda, MD).  BALB/c-
derived CT26 colorectal cancer cells were from ATCC (Manassas, Virginia).  Stable 
GCCTM-expressing CT26 cell lines were described previously (5). 
ELISA.  GCC and AV –specific ELISAs were described previously (5).  Briefly, 
immunosorbent plates (Nunc, Rochester, New York) were coated with purified GCC-
6xHis at 10 µg/ml or with irrelevant adenoviral particles at 1x107 IFU/ml.  Coated plates 
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were incubated with serum collected from immunized mice and specific antibodies were 
detected with HRP-conjugated goat anti-mouse immunoglobulin (Jackson Laboratories) 
and ABTS substrate (Pierce, Rockford, Illinois). 
ELISpot.  GCC, AV and β-galactosidase -specific ELISpots were described previously 
(5).  Briefly, multiscreen filtration plates (Millipore, Billerica, Massachusetts) were coated 
with anti-mouse IFNγ-capture antibody (BD Pharmingen, San Jose, California) and 
splenocytes were plated at 250,000 or 500,000 cells per well for CD8+ and CD4+ T cell 
responses, respectively.  For CD8+ T cell responses, MC38 cells expressing GCC or 
LacZ were treated with 1000 U/ml recombinant mouse IFNγ (EMD Biosciences, San 
Diego, California) for 48 h to increase MHC expression and were used as stimulator 
cells.  For SIINFEKL-specific responses, MC57G cells stably expressing a SIINFEKL 
minigene were used as stimulator cells.  For CD4+ T cell responses, splenocytes were 
incubated on antibody-coated plates with GCC-6xHis or irrelevant purified adenovirus 
particles.  After ~24 h of stimulation, spots were developed with biotinylated anti-IFNγ 
detection antibody (BD Pharmingen) and alkaline phosphatase-conjugated streptavidin 
(Pierce), followed by NBT/BCIP substrate (Pierce).  Spot forming cells (SFCs) were 
enumerated using computer-assisted video imaging analysis (ImmunoSpot v3, Cellular 
Technology, Shaker Heights, Ohio). 
Metastatic Tumors and PET/microCT.  For lung metastases, BALB/c mice were 
immunized 7 d prior to administration of 5x105 CT26-GCCTM cells via tail vein injection.  
Mice received 0.45 mCi 18F-fluorodeoxyglucose 14 d after tumor challenge, and PET 
images were collected 2 h later on a Mosaic scanner (Philips Medical Systems, 
Andover, Massachusetts).  CT images were acquired on a microCAT II (Imtek, Inc, 
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Knoxville, Tennessee).  Mice were then euthanized and metastases enumerated (5).  
DSS Colitis.  Female 6 wk old C57BL/6 mice were immunized with GCC-AV or Control-
AV, RV and VV at 28 day intervals, a heterologous prime boost regimen (PBB) that 
maximizes GCC-specific antitumor responses (5).  Mice were treated 4 d after the final 
immunization with 4% dextran sulfate sodium (DSS; Sigma Aldrich, St. Louis, Missouri) 
ad libitum in the drinking water for 7 d, and body weights were monitored daily 
beginning at DSS administration (28, 29).  Some mice were euthanized on day 9 
following the first DSS administration and tissues collected for assessment of colitis. 
Colitis Assessment.  Intestinal contents were scored for stool consistency (normal = 0, 
slightly loose feces = 1, loose feces = 2, watery diarrhea = 3) and visible fecal blood 
(normal = 0, slightly bloody = 1, bloody = 2, blood in whole colon = 3) (29).  
Subsequently, intestines where formalin-fixed, paraffin-embedded, stained with 
hematoxylin & eosin and scored by a blinded pathologist (RB).  The histological score 
represents the arithmetic sum of the epithelial damage score (normal = 0, loss of goblet 
cells = 1, loss of goblet cells in large areas = 2, loss of crypts = 3, loss of crypts in large 
area = 4) and inflammation score (no infiltrate = 0, infiltrate around crypt base = 1, 
infiltrate reaching muscularis mucosae = 2, extensive infiltration reaching the muscularis 
mucosae, thickening of the mucosa with abundant edema = 3, infiltration of the 
submucosa = 4) (28). 
Tumorigenesis.  Male and female 4 wk old APCmin/+ mice were immunized with AV, RV 
and VV as above and tumorigenesis quantified at 14 wks old.  For inflammation-
associated tumorigenesis, female 6 wk old C57BL/6 mice were immunized as above 
with AV, RV and VV.  A single dose of axozymethane (AOM; Sigma Aldrich) 15 mg/kg 
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was administered intraperitoneally 3 d before the final immunization and 4% DSS 
administration began 7 d later.  Following 7 d of DSS, water was returned to the mice 
for 14 d, followed by 2 more cycles of 3% DSS (24).  Tumorigenesis was quantified 10 
days after the final cycle of DSS.  Tumors were enumerated and their size quantified 
under a dissecting microscope.  Tumor burden in APCmin/+ mice was determined by 
calculating the sum of the (diameter)2 of individual tumors for the small and large 
intestines in each mouse (26).  Intestinal tissues were processed for H&E staining and 
tumors from AOM-DSS treated mice were confirmed by histology and graded (AB).  
RESULTS 
GCC induces lineage-specific immune effector cell responses.  The extracellular 
domain of GCC is not homologous with other guanylyl cyclases, limiting the possibility 
and extent of central tolerance, and is a target for immunotherapy to prevent GCC-
expressing metastatic colorectal cancer in mice (1, 2, 5).  Here, GCC+/+ and GCC-/- 
C57BL/6 mice were immunized with adenovirus (AV) expressing the extracellular 
domain of GCC (GCC-AV) or Control-AV and immune responses quantified after 10 d.  
GCC-/- mice, in which tolerance to the target antigen is absent, were employed as a 
positive control (5).  While GCC-specific CD4+ T cell (Fig. 1A) and antibody (Fig. 1C) 
responses were produced in GCC-/- mice upon a single immunization with GCC-AV, 
these responses were absent in GCC+/+ mice (Fig. 1A and C).  Equivalent adenovirus-
specific antibody (Fig. 1B) and CD4+ T cell (Fig. 1D) responses in GCC+/+ and GCC-/- 
mice confirm that eliminating GCC expression does not alter antigen-specific immune 
responses beyond those to GCC. 
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To measure CD8+ T cell responses, mice were immunized with GCC-AV or LacZ-AV 
and GCC or β-galactosidase -specific CD8+ T cell responses were measured 10 d later 
upon ex vivo recognition of GCC or β-galactosidase -expressing colon cancer cells.  In 
contrast to CD4+ T cell and antibody responses in GCC+/+ mice, GCC-specific CD8+ T 
cell responses were generated in GCC+/+ mice, revealed by specific recognition of GCC, 
but not β-galactosidase, -expressing cells upon GCC-AV immunization (Fig. 1E) and 
specific recognition of β-galactosidase, but not GCC, -expressing cells upon LacZ-AV 
immunization (Fig. 1F).  Responses to GCC-AV immunization were attenuated in 
GCC+/+, compared to GCC-/-, mice (Fig. 1G) reflecting partial CD8+ T cell tolerance in 
GCC+/+ mice.  Tolerance was GCC-specific since CD8+ T cell responses to the 
ovalbumin257–264 epitope SIINFEKL were equivalent in GCC+/+ and GCC-/- mice (Fig. 
1H). 
GCC immunization induces antitumor immunity opposing parenchymal metastases.  
Mice were immunized with GCC-AV or Control-AV, followed 7 d later by intravenous 
challenge with GCC-expressing CT26 colon cancer cells.  Tumor burden revealed by 
18F-fluorodeoxyglucose PET/microCT was nearly eliminated in GCC-immunized mice 
compared to control immunized mice (Fig. 2A).  Indeed, the number of tumors was 
reduced ~75% in GCC, compared to control, –immunized mice (p<0.001; Fig. 2B, 2C).  
Induction of CD8+ T cell, but not CD4+ T cell or antibody responses to GCC (Fig. 1), 
underscores the importance of lineage-specific immune effector cell responses in 
mediating GCC-targeted antitumor immunity. 
GCC immunization does not amplify inflammatory bowel disease.  Despite the 
generation of CD8+ T cell responses to GCC and effective antitumor immunity, mice 
13 
 
immunized with GCC-AV were without clinical signs of intestinal inflammation including 
diarrhea, rectal bleeding and weight loss.  Moreover, they were free of autoimmune 
inflammation by histopathology.  To determine the impact of GCC-targeted immunity on 
inflammatory bowel disease, mice were immunized with GCC-AV or Control-AV, 
followed by GCC-RV or Control-RV and GCC-VV or Control-VV at 28 day intervals (5).  
Indeed, while this heterologous prime-boost regimen induces maximum antitumor 
immunity (5), it was without effect on autoimmunity for up to 119 days beyond the 
initiation of immunization (Fig. 3, Supplementary Fig. 1-3).  Following the final 
immunization, mice were administered 4% DSS in drinking water ad libitum for 7 d and, 
subsequently, weights were monitored as a marker of inflammatory bowel disease (Fig. 
3A).  Preliminary experiments established dose-dependent disease upon DSS 
administration and defined 4% DSS as inducing moderate disease (data not shown).  
Control and GCC -immunized mice were without signs of inflammatory bowel disease, 
maintained weight (Fig. 3A) and remained free of gross or histological evidence of 
disease (Fig. 3B, C and D; Supplementary Fig. 3).  In contrast, DSS treatment of control 
and GCC -immunized mice induced pronounced weight loss, achieving a nadir at ~9 d 
followed by complete recovery at ~14 d after discontinuing DSS (Fig. 3A).  Importantly, 
weight loss and recovery were identical in control and GCC -immunized mice (Fig. 3A; 
P >0.05 Bonferroni's multiple comparison test on area the under the curve values).  
Moreover, weight changes in immunized groups were similar to those in naïve mice, 
confirming that viral immunization did not impact disease (Supplementary Fig. 2). 
Colons were collected from mice 9 d after initiating DSS, examined and processed for 
histopathology (Fig. 3D; Supplementary Fig. 3).  While naïve and immunized mice in the 
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absence of DSS had normal stool, all groups receiving DSS experienced diarrhea (Fig. 
3B).  Consistent with previous observations in which intestinal bleeding declines by ~9 d 
(29), fecal blood was not detected in any group (Fig. 3C).  Histopathology confirmed 
that inflammation and epithelial damage were virtually identical in naïve, control, and 
GCC -immunized groups (Fig. 3D; Supplementary Fig. 3).  Moreover, immunization 
during, rather than prior to, DSS-induced colitis also had no affect on disease severity 
(Supplementary Figs. 1-3).  Importantly, this first examination of systemic immunity to 
intestinal antigens in the context of fulminant inflammatory bowel disease suggests that 
autoimmunity and acute inflammation are not contraindications to immunotherapy 
directed to cancer mucosa antigens. 
GCC immunization does not promote colon tumorigenesis.  The APC gene is mutated 
early in >80% of sporadic human colorectal cancers and its germline mutation underlies 
the inherited intestinal neoplastic syndrome familial adenomatous polyposis, 
establishing APC mutation as an early event in human colorectal tumorigenesis (30).  
Moreover, mice heterozygous for mutant APC (APCmin/+) develop intestinal polyps and 
are the most frequently used model of colorectal tumorigenesis (31).  Here, 
tumorigenesis in APCmin/+ mice was examined following control or GCC –based 
immunization.  Again, the heterologous prime-boost regimen was employed to 
maximize GCC-specific immune responses.  APCmin/+ mice were immunized with control 
or GCC-AV, RV and VV at 4, 8 and 12 wk of age, respectively, and tumor burden 
quantified 2 wk later.  Unlike humans, APCmin/+ mice develop tumors in small and large 
intestine (31).  Tumorigenesis in small (Fig. 4A, B) and large (Fig. 4C) intestine in 
control and GCC -immunized mice was comparable, reflected by histolopathology (Fig. 
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4A) and tumor burden (Fig. 4B, C). Histopathology confirmed that tumors were 
adenomatous polyps in both control and GCC -immunized APCmin/+ mice and did not 
progress to invasive carcinoma (Fig. 4A). 
These observations were extended to colon cancer associated with inflammatory bowel 
disease, employing the AOM-DSS model of colitis-associated colorectal cancer.  AOM 
is a procarcinogen, which when metabolized forms O6-methylguanine and induces the 
formation of distal colon tumors in rodents (32).  Moreover, repeated exposure of AOM-
treated mice to DSS induces chronic inflammation, mimicking human inflammatory 
bowel disease, and dramatically enhances AOM-induced tumorigenesis (33).  Here, 
mice were immunized with control or GCC-AV, RV and VV at 6, 10 and 14 wk of age, 
respectively.  A single dose of 15 mg/kg AOM was administered 3 d before the final 
immunization.  The first cycle of 4% DSS initiated 7 d after AOM treatment and was 
followed by 2 more cycles of 3% DSS with 2 wk between cycles (24).  This regimen 
produced tumors in 100% of control and GCC -immunized mice (data not shown), 
specifically restricted to the distal colon (Fig. 4D).  As observed in APCmin/+ mice, tumor 
number (Fig. 4E) and size (Fig. 4F) were identical in control and GCC -immunized mice.  
Histopathological analysis of tissue sections revealed similar incidence of carcinoma in 
situ in control (19.6%) and GCC (25%) -immunized mice (P = 0.5184, Fisher’s exact 
test; Table 1).  
DISCUSSION 
Cancer mucosa antigens comprise an emerging category of self-antigens expressed 
normally in immunologically privileged mucosal compartments and by tumors originating 
therein (1, 2, 5).  Universal expression of mucosa-restricted antigens by derivative 
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tumors offers a unique solution to the application of self-antigens from immunologically 
privileged sites to tumor immunotherapy. This approach leverages the established 
immunological partitioning of systemic and mucosal compartments (3, 4).  Expression 
confined to mucosae restricts antigen access to the systemic compartment, limiting 
tolerance opposing antitumor immunity.  Conversely, asymmetry in signaling across 
compartments, wherein systemic immune responses rarely extend to mucosae, limits 
the risk of autoimmune disease following systemic immunization.  In that context, 
immunization with the intestinal cancer mucosa antigen GCC produced lineage-specific 
immune cell responses in the systemic compartment, comprising CD8+ T, but not CD4+ 
T or B, cells.  Lineage-specific tolerance reflects thymic and/or peripheral mechanisms, 
rather than antigenicity, since GCC-/- mice responded to GCC in all arms of the adaptive 
immune system, while in GCC+/+ mice, GCC elicited only CD8+ T cell responses. 
Incomplete systemic tolerance to GCC presumably reflects anatomical, functional and 
immunological compartmentalization wherein sequestration of mucosal antigens 
provides insufficient antigen for complete systemic tolerance (34, 35).  Importantly, 
CD8+ T cell responses to GCC alone were sufficient for immunoprophylaxis, and a 
single immunization with GCC-AV dramatically reduced pulmonary colon cancer 
metastases. 
There remains an unresolved issue regarding autoimmunity surrounding the use of self-
antigens generally, and cancer mucosa antigens specifically, as immunotherapeutic 
targets (6-8).  Immune effectors to self-antigens could amplify autoimmune disease and 
chronic inflammation which, in turn, promotes carcinogenesis (9).  With respect to 
intestinal cancer mucosa antigens, immune effectors targeting mucosal antigens could 
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potentiate inflammatory bowel disease and/or tumorigenesis, reflecting disruption of 
normal mucosal barriers creating novel effector access to compartmentalized antigens, 
amplifying chronic inflammation.  Those considerations notwithstanding, immunization 
of mice with GCC activated systemic CD8+ T cell responses that, while mediating 
effective parenchymal anti-metastatic colon cancer immunity, spared GCC-expressing 
intestinal epithelium from autoimmune disease.  Further, systemic GCC immunity 
induced by a heterologous prime-boost regimen producing maximum effector responses 
(5) did not influence fulminant intestinal inflammation associated with chemically-
induced colitis.  Moreover, GCC immunity failed to promote intestinal carcinogenesis 
reflecting germline mutations in a key tumor suppressor or chronic inflammation.  These 
studies, which are the first to examine the impact of systemic immunity to an intestine-
specific self-antigen on inflammatory bowel disease or inflammation-associated colon 
tumorigenesis, support the safety of GCC immunization in patients at risk for 
inflammatory bowel disease or hereditary colorectal cancer.  Indeed, GCC immunization 
has substantial translational potential, reflecting the universal expression of GCC in 
metastatic human colorectal cancer (14-16).  While GCC immunogenicity has not yet 
been explored in patients, studies here reveal uncoupling of systemic antitumor 
immunity and intestinal autoimmunity through immune compartmentalization and 
support examination of GCC immunotherapy for metastatic colorectal cancer. 
Preservation of immune compartmentalization and tissue integrity in the face of 
mucosa-targeted immune effector cells and fulminant barrier disruption likely reflects the 
convergence of parallel homeostatic mechanisms.  Compartmentalization is supported 
by tissue-restricted lymphocyte recirculation mediated by chemokine and adhesion 
18 
 
molecules, particularly the interactions of addressin and integrins and selectins, which 
define tissue-specific lymphocyte migration (1, 36-38).  The local lymphoid 
microenvironment imprints new circulation patterns during activation, and effector T 
cells from mesenteric lymph nodes home to the gut wall, lamina propria, Peyer’s 
patches, and mesenteric lymph nodes while those from peripheral lymph nodes migrate 
to spleen and peripheral lymph nodes (38).  Moreover, the lineage specificity of effector 
responses to GCC may be particularly advantageous since autoreactive CD4+ T cells 
are more efficient mediators of autoimmunity than CD8+ T cells.  Thus, CD4+ T cells 
targeted to a gastric self antigen (39) or commensal bacterial antigen (40) induce 
autoimmunity in mice.  Also, experimental autoimmune diseases such as autoimmune 
encephalomyelitis (41), thyroiditis (42), colitis (43) and oophritis (44) are CD4+ T cell-
mediated.  By contrast, CD8+ T cells are infrequent mediators of autoimmune disease, 
and CD8+ T cell-mediated colitis has been reported in only one model, requiring 
adoptive transfer of large numbers of transgenic CD8+ T cells (45).  Further, in humans, 
MHC II genes provide significant disease susceptibility, and HLA-DQ2/DR3, HLA-
DQ6/DR2, and HLA-DQ8/DR4 haplotypes are associated with 90% of autoimmune 
disease (46). 
The present results have substantial implications for the control of metastatic colorectal 
cancer in patients.  The majority of colorectal cancer cases are sporadic, reflecting 
environmental and genetic risk factors (25).  However, of the ~1 million patients 
developing colorectal cancer worldwide, ~2% are associated with inflammatory bowel 
disease and ~5-10% reflect the inherited syndromes hereditary nonpolyposis colorectal 
cancer (HNPCC) and familial adenomatous polyposis (FAP) (25).  These diseases are 
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associated with a cancer penetrance of ~20% in inflammatory bowel disease and 70-
100% in hereditary cancer syndromes (25).  Indeed, prophylactic colectomy is routinely 
employed in those patients at greatest risk for developing colorectal cancer.  Therefore, 
prophylactic GCC-specific immunization may be a useful adjunct for cancer control in 
these populations.  While immunization will not prevent the development of primary 
tumors (Fig. 4), GCC-based immunity could protect against systemic metastases.  
Importantly, GCC-targeted immunity provided effective anti-metastatic therapy without 
exacerbating intestinal inflammation or primary carcinogenesis, suggesting that cancer 
mucosa antigen immunotherapy is not contraindicated in patients with inflammatory 
bowel disease or inherited colorectal cancer syndromes. 
Interestingly, results here contrast with prior studies examining immunotherapy targeting 
self-antigens in mouse models of intestinal carcinogenesis (47-49).  While mechanisms 
underlying these differences remain to be defined, immune responses in earlier studies 
were characterized by antibody production, in addition to T cell induction.  Antibodies 
have established efficacy in animal models and humans which may extend to primary 
colorectal tumorigenesis.  Indeed, cetuximab (Eribitux, anti-EGFR monoclonal 
antibody), bevacizumab (Avastin, anti-VEGF monoclonal antibody), and trastuzumab 
(Herceptin, anti-EGFR monoclonal antibody) provide clinically-important antitumor 
efficacy against various tumors .  Moreover, antitumor effects induced by immunization 
against 5T4, a human oncofetal antigen, appear to be mediated exclusively by 
antibodies (50).  In that context, GCC-specific immunization does not induce IgG 
responses in GCC+/+ mice, the absence of which may restrict efficacy against primary 
tumors.  Studies employing passive transfer of serum from immunized GCC-/- mice to 
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APCmin/+ GCC+/+ mice may reveal primary antitumor efficacy that is absent in the current 
immunization paradigm which will inform the development of the next generation of 
immunization regimens that activate both CD8+ T cell and antibody responses. 
GCC-targeted immunity which protects against parenchymal colon cancer metastases 
did not exacerbate inflammatory bowel disease or promote inflammation- or genetically-
induced intestinal carcinogenesis.  These observations support the utility of GCC-
targeted immunotherapy for cancer prevention and control in patients at risk for 
developing systemic metastases, including those with inflammatory bowel disease, 
hereditary colorectal cancer syndromes, and sporadic colorectal cancer.  Moreover, 
GCC-based vaccines could be applied to patients with esophageal and gastric cancer, 
reflecting the role of intestinal metaplasia and the associated novel ectopic expression 
of that antigen in those malignancies (15).  Beyond the GI tract, the present 
observations suggest the utility and safety of exploiting immunological 
compartmentalization to achieve anti-metastatic therapy in tumors originating from other 
mucosae including oral, respiratory, mammary, and urogenital for the treatment of 
cancers of the head and neck, lung, breast, vagina and bladder, respectively.  Indeed, 
the established principles of immune compartmentalization in the context of the present 
results with GCC underscore the importance of defining the generalizability of cancer 
mucosa antigens as targets for immunotherapy of mucosa-derived tumors (1, 2, 5). 
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Table 1.  Histopathology of colitis-associated colorectal tumors. 
Immunization 
 
Tubular adenoma 
 
Carcinoma in situ 
  
(% of histologically confirmed tumors) 
Control 
 
80.4% 
 
19.6% 
GCC 
 
75.0% 
 
25.0%† 
†P = 0.5184, Fisher’s exact test 
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FIGURE LEGENDS 
Figure 1.  GCC-specific CD4+ T cell and antibody tolerance.  A, GCC-specific CD4+ 
T cell responses in Control-AV- or GCC-AV-immunized GCC+/+ (+/+) and GCC-/- (-/-) 
C57BL/6 mice, measured by IFNγ ELISpot upon restimulation with recombinant GCC-
6xHis protein (* P <0.05, two-sided Student’s t test on values at 50 µg/ml).  B, AV-
specific CD4+ T cell responses in GCC-AV-immunized GCC+/+ (+/+) and GCC-/- (-/-) 
C57BL/6 mice, measured by IFNγ ELISpot upon restimulation with AV particles (*** P 
<0.001, # P >0.05, two-sided Student’s t test on values at 1x108 IFU/ml).  Data in A and 
B indicate pooled analysis of N=2-3 mice per group, and are representative of four 
independent experiments.  C, ELISA analysis of GCC-specific IgG antibody responses 
in GCC+/+ (+/+) or GCC-/- (-/-) C57BL/6 mice 14 days after immunization with GCC-AV or 
Control-AV.  Data indicate means of N=3 mice per group at reciprocal serum dilutions of 
25, 50, 100 and 200 (*** P<0.001, two-way ANOVA).  Data are representative of three 
independent experiments.  D, ELISA analysis of AV-specific IgG antibody responses in 
GCC+/+ (+/+) or GCC-/- (-/-) C57BL/6 mice 10-14 days after immunization with AV or in 
AV-naïve mice (negative control).  Data indicate means of N=4 AV-immunized mice per 
genotype or pooled samples of three control-immunized mice per genotype at reciprocal 
serum dilutions of 100, 200, 400 and 800 (*** P <0.001, # P >0.1, two-way ANOVA).  E, 
GCC-specific CD8+ T cell responses in GCC+/+ C57BL/6 mice following LacZ-AV 
(control) or GCC-AV immunization, measured by IFNγ ELISpot employing GCC-
expressing colorectal cancer cells as stimulators.  F, β-galactosidase-specific CD8+ T 
cell responses in GCC+/+ C57BL/6 mice following LacZ-AV or GCC-AV (control) 
immunization, measured by IFNγ ELISpot employing β-galactosidase-expressing 
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colorectal cancer cells as stimulators.  Data in E and F indicate pooled analysis of N=2 
mice per group, and are representative of six independent experiments (*** P <0.001, 
two-sided Student’s t test).  G, GCC-specific CD8+ T cell responses in GCC+/+ (+/+) and 
GCC-/- (-/-) C57BL/6 mice following GCC-AV immunization, measured by IFNγ ELISpot 
as in E.  Data indicate pooled analysis of N=2 mice per group, and are representative of 
two independent experiments (** P <0.01, two-sided Student’s t test).  H, SIINFEKL-
specific CD8+ T cell responses in GCC+/+ (+/+) and GCC-/- (-/-) C57BL/6 mice following 
NP/SIINFEKL-AV immunization, measured by IFNγ ELISpot upon restimulation with 
SIINFEKL-expressing stimulator cells.  Data represent three independent experiments 
examining SIINFEKL or β-galactosidase -specific responses (# P >0.9, two-sided 
Student’s t test).  Error bars in A-H indicate standard deviation.   
Figure 2.  GCC-specific immunotherapy against colon cancer metastases in lung.  
BALB/c mice were immunized with Control-AV or GCC-AV and then challenged with 
5x105 CT26-GCCTM cells by tail vein injection 7 days later.  A, on day 14 after 
challenge, metastases were visualized by PET/microCT.  Images indicate merged PET 
and microCT images and lungs are outlined for clarity.  Images are representative of 
N=5-7 mice per immunization.  B, lungs were removed and stained with India ink to 
visualize lung nodules.  C, lung nodules were enumerated upon visual inspection.  Data 
indicate means of N=12 mice per immunization (*** P <.001, two-sided Student’s t test).  
Error bars indicate 95% confidence intervals.  
Figure 3.  GCC immunization does not intensify mucosal autoimmunity in 
experimental colitis.  A, female C57BL/6 mice were immunized with Control-AV or 
GCC-AV and boosted sequentially with RV and VV at 28 day intervals.  Four days later, 
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mice were treated with a 7 day course of 4% DSS ad libitum in the drinking water, 
followed by normal water.  Mouse weights were monitored daily.  Data indicate means 
and error bars indicate 95% confidence intervals (P >0.05 Bonferroni’s multiple 
comparison’s test on area under the curve (AUC) values, Control vs. GCC –immunized 
DSS treatment groups, Supplementary Fig. 1).  B-D, some mice were euthanized on 
day 9 for examination of disease markers including diarrhea (B), fecal blood (C) and 
histology (D).  Data in B-D indicate N=5 mice per group and error bars indicate standard 
deviation (# P >0.05 Bonferroni’s multiple comparison test). 
Figure 4.  GCC-specific immunization does not amplify tumorigenesis in genetic 
and inflammatory models of colorectal cancer.  A-C,  APCmin/+ C57BL/6 mice were 
immunized with Control-AV or GCC-AV and boosted sequentially with RV and VV at 28 
day intervals beginning at 4 weeks of age.  Two weeks after the final immunization 
intestines were collected, examined by histology (A) and tumor burden was quantified in 
small (B) and large intestine (C).  Error bars indicate 95% confidence intervals (# P 
>0.05 two-sided Welch’s t test).  D-F, female C57BL/6 mice were immunized with 
Control-AV or GCC-AV and boosted sequentially with RV and VV at 28 day intervals 
beginning at 6 weeks of age.  The procarcinogen AOM was administered 3 days before 
the final immunization.  Seven days later, 3 cycles of DSS were initiated with 14 days of 
water between each cycle.  D, colons were collected 10 days after the final cycle and 
examined.  Tumor number (E) and size (F) were determined under a dissecting 
microscope.  Error bars indicate 95% confidence intervals (# P >0.05 two-sided Welch’s 
t test). 
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SUPPLEMENTAL MATERIAL 
Supplemental Figure 1.  GCC immunization does not intensify mucosal 
autoimmunity during active experimental colitis.  A, female C57BL/6 mice were 
treated with a 7 day course of DSS ad libitum in the drinking water, followed by normal 
water.  Mice were immunized with Control-AV or GCC-AV on day 5 and boosted 
sequentially with RV and VV at 7 day intervals.  Mouse weights were monitored daily.  
Data indicate means and error bars indicate 95% confidence intervals (P >0.05 
Bonferroni’s multiple comparison’s test on area under the curve (AUC) values, Control 
vs. GCC -immunized DSS treatment groups, Supplemental Fig. 2).  B-D, mice were 
euthanized on day 23 for examination of disease markers including diarrhea (B), fecal 
blood (C) and histology (D).  Data in B-D indicate N=5-11 mice per group and error bars 
indicate standard deviation (# P >0.05 Bonferroni’s multiple comparison test). 
Supplemental Figure 2.  Area under the curve (AUC) analysis of DSS colitis.  
Negative area-under-the-curve (AUC) peaks were calculated on weight curves from 
untreated naïve, control-immunized and GCC-immunized mice and those treated with 
DSS ad libitum.  Mice were immunized by heterologous prime boost prior to DSS 
administration (PBB→DSS; Figure 3) or beginning on day 5 after DSS initiation 
(DSS→PBB; Supplemental Figure 1).  ** P <0.01, *** P <0.001, # P >0.05 Bonferroni’s 
multiple comparison test. 
Supplemental Figure 3.  Histological scores of selected treatment regimens.  
Colons of mice from treatment regimens including acute, intermediate and chronic 
immunization as well as immunization prior to, or during, DSS-induced IBD were scored 
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by histology for epithelial damage and inflammation.  # P >0.05 Bonferroni’s multiple 
comparison test. 
 
